State of New Jersey Common Pension Fund D Sells 620 Shares of Thermo Fisher Scientific Inc. $TMO

State of New Jersey Common Pension Fund D lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,924 shares of the medical research company’s stock after selling 620 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Thermo Fisher Scientific were worth $51,868,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. Keeler Thomas Management LLC purchased a new stake in Thermo Fisher Scientific in the second quarter worth $786,000. Leelyn Smith LLC grew its position in Thermo Fisher Scientific by 7.9% during the second quarter. Leelyn Smith LLC now owns 8,206 shares of the medical research company’s stock worth $3,327,000 after buying an additional 601 shares in the last quarter. CNB Bank boosted its holdings in shares of Thermo Fisher Scientific by 13.3% in the 2nd quarter. CNB Bank now owns 2,112 shares of the medical research company’s stock worth $856,000 after purchasing an additional 248 shares in the last quarter. PKO Investment Management Joint Stock Co lifted its stake in shares of Thermo Fisher Scientific by 25.0% in the 2nd quarter. PKO Investment Management Joint Stock Co now owns 7,500 shares of the medical research company’s stock valued at $3,041,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Sage Mountain Advisors LLC increased its stake in Thermo Fisher Scientific by 6.3% in the 2nd quarter. Sage Mountain Advisors LLC now owns 2,580 shares of the medical research company’s stock worth $1,046,000 after purchasing an additional 153 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of several research analyst reports. Citigroup increased their price objective on Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. HSBC restated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating for the company. Nineteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $595.75.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock valued at $13,990,971 in the last 90 days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 0.2%

Shares of TMO stock opened at $573.07 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.50. The stock’s 50 day simple moving average is $504.04 and its two-hundred day simple moving average is $453.30. The company has a market cap of $216.40 billion, a PE ratio of 33.11, a price-to-earnings-growth ratio of 3.24 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the business posted $5.28 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.